Clinical electrophysiological effects of intravenous recainam

An antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias

G. K. Feld, R. M. Luceri, A. J. Greenspon, B. N. Singh, L. N. Horowitz, D. M. Capuzzi, V. B. Frame, Robert J Myerburg

Research output: Contribution to journalArticle

Abstract

This open-label, multicenter study was designed to assess the electrophysiological properties of intravenous recainam, an investigational Class I antiarrhythmic agent. In 25 patients undergoing electrophysiological studies for the evaluation of arrhythmias, recainam was administered intravenously in a loading infusion (0.1 mg/kg/min) for 40 minutes, followed by a maintenance infusion (0.02 mg/kg/min) until the completion of the study. Electrophysiological measurements were obtained at baseline, 30 minutes after initiation of the loading infusion, and 30 minutes after termination of the infusion during washout. Conduction intervals, refractory periods, and sinus node recovery times were measured during sinus rhythm and during atrial or ventricular pacing. Vital signs were obtained and recorded before, during, and after recainam infusion. The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion. Recainam produced a generalized slowing of intracardiac conduction. The mean intraatrial conduction time, measured at an atrial paced cycle length of 600 msec, increased during recainam loading infusion by 44%, from 38.8 ± 2.8 to 53.0 ± 5.4 msec; intranodal conduction time increased by 10%, from 102.0 ± 5.5 to 112.1 ± 5.2 msec; and infranodal conduction time increased by 31% from 53.1 ± 3.0 to 70.7 ± 3.8 msec. Slowed conduction persisted during washout. The mean right atrial effective refractory period was significantly prolonged (+7% at 600 msec cycle length and +8% at 450 msec cycle length, P < 0.05 and P < 0.01, respectively) during recainam loading and remained so during washout. However, the mean effective refractory period of the atrioventricular node was significantly prolonged only during the recainam loading infusion while pacing at 450-msec cycle length (+8%, P < 0.05). In contrast, the mean effective refractory period of the right ventricle was not changed during or immediately after the infusion, but was significantly shortened 30 minutes later (-4%, P < 0.05). Two of 25 patients (8%) developed adverse reactions requiring termination of the infusion. Five other patients (20%) developed less serious side effects during the recainam infusion, all of which resolved spontaneously and did not require termination of the infusion. The results demonstrate that recainam prolongs conduction in atrial, ventricular, and specialized cardiac conduction tissues. Recainam also prolongs atrial refractory periods, but has little or no effect on the sinus node or on AV nodal and right ventricular refractory periods. Thus, recainam is a Class I antiarrhythmic agent with a combination of electrophysiological properties suggesting its potential utility in the treatment of atrial and ventricular arrhythmias.

Original languageEnglish
Pages (from-to)1129-1137
Number of pages9
JournalPACE - Pacing and Clinical Electrophysiology
Volume14
Issue number7
StatePublished - Jan 1 1991

Fingerprint

Anti-Arrhythmia Agents
Cardiac Arrhythmias
Therapeutics
Sinoatrial Node
recainam
Atrioventricular Node
Vital Signs
Multicenter Studies
Heart Ventricles
Arterial Pressure
Heart Rate
Maintenance

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical electrophysiological effects of intravenous recainam : An antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias. / Feld, G. K.; Luceri, R. M.; Greenspon, A. J.; Singh, B. N.; Horowitz, L. N.; Capuzzi, D. M.; Frame, V. B.; Myerburg, Robert J.

In: PACE - Pacing and Clinical Electrophysiology, Vol. 14, No. 7, 01.01.1991, p. 1129-1137.

Research output: Contribution to journalArticle

Feld, G. K. ; Luceri, R. M. ; Greenspon, A. J. ; Singh, B. N. ; Horowitz, L. N. ; Capuzzi, D. M. ; Frame, V. B. ; Myerburg, Robert J. / Clinical electrophysiological effects of intravenous recainam : An antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias. In: PACE - Pacing and Clinical Electrophysiology. 1991 ; Vol. 14, No. 7. pp. 1129-1137.
@article{32bed580edf946f9928a3292374d2c02,
title = "Clinical electrophysiological effects of intravenous recainam: An antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias",
abstract = "This open-label, multicenter study was designed to assess the electrophysiological properties of intravenous recainam, an investigational Class I antiarrhythmic agent. In 25 patients undergoing electrophysiological studies for the evaluation of arrhythmias, recainam was administered intravenously in a loading infusion (0.1 mg/kg/min) for 40 minutes, followed by a maintenance infusion (0.02 mg/kg/min) until the completion of the study. Electrophysiological measurements were obtained at baseline, 30 minutes after initiation of the loading infusion, and 30 minutes after termination of the infusion during washout. Conduction intervals, refractory periods, and sinus node recovery times were measured during sinus rhythm and during atrial or ventricular pacing. Vital signs were obtained and recorded before, during, and after recainam infusion. The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion. Recainam produced a generalized slowing of intracardiac conduction. The mean intraatrial conduction time, measured at an atrial paced cycle length of 600 msec, increased during recainam loading infusion by 44{\%}, from 38.8 ± 2.8 to 53.0 ± 5.4 msec; intranodal conduction time increased by 10{\%}, from 102.0 ± 5.5 to 112.1 ± 5.2 msec; and infranodal conduction time increased by 31{\%} from 53.1 ± 3.0 to 70.7 ± 3.8 msec. Slowed conduction persisted during washout. The mean right atrial effective refractory period was significantly prolonged (+7{\%} at 600 msec cycle length and +8{\%} at 450 msec cycle length, P < 0.05 and P < 0.01, respectively) during recainam loading and remained so during washout. However, the mean effective refractory period of the atrioventricular node was significantly prolonged only during the recainam loading infusion while pacing at 450-msec cycle length (+8{\%}, P < 0.05). In contrast, the mean effective refractory period of the right ventricle was not changed during or immediately after the infusion, but was significantly shortened 30 minutes later (-4{\%}, P < 0.05). Two of 25 patients (8{\%}) developed adverse reactions requiring termination of the infusion. Five other patients (20{\%}) developed less serious side effects during the recainam infusion, all of which resolved spontaneously and did not require termination of the infusion. The results demonstrate that recainam prolongs conduction in atrial, ventricular, and specialized cardiac conduction tissues. Recainam also prolongs atrial refractory periods, but has little or no effect on the sinus node or on AV nodal and right ventricular refractory periods. Thus, recainam is a Class I antiarrhythmic agent with a combination of electrophysiological properties suggesting its potential utility in the treatment of atrial and ventricular arrhythmias.",
author = "Feld, {G. K.} and Luceri, {R. M.} and Greenspon, {A. J.} and Singh, {B. N.} and Horowitz, {L. N.} and Capuzzi, {D. M.} and Frame, {V. B.} and Myerburg, {Robert J}",
year = "1991",
month = "1",
day = "1",
language = "English",
volume = "14",
pages = "1129--1137",
journal = "PACE - Pacing and Clinical Electrophysiology",
issn = "0147-8389",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Clinical electrophysiological effects of intravenous recainam

T2 - An antiarrhythmic drug under investigation for the treatment of ventricular and supraventricular arrhythmias

AU - Feld, G. K.

AU - Luceri, R. M.

AU - Greenspon, A. J.

AU - Singh, B. N.

AU - Horowitz, L. N.

AU - Capuzzi, D. M.

AU - Frame, V. B.

AU - Myerburg, Robert J

PY - 1991/1/1

Y1 - 1991/1/1

N2 - This open-label, multicenter study was designed to assess the electrophysiological properties of intravenous recainam, an investigational Class I antiarrhythmic agent. In 25 patients undergoing electrophysiological studies for the evaluation of arrhythmias, recainam was administered intravenously in a loading infusion (0.1 mg/kg/min) for 40 minutes, followed by a maintenance infusion (0.02 mg/kg/min) until the completion of the study. Electrophysiological measurements were obtained at baseline, 30 minutes after initiation of the loading infusion, and 30 minutes after termination of the infusion during washout. Conduction intervals, refractory periods, and sinus node recovery times were measured during sinus rhythm and during atrial or ventricular pacing. Vital signs were obtained and recorded before, during, and after recainam infusion. The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion. Recainam produced a generalized slowing of intracardiac conduction. The mean intraatrial conduction time, measured at an atrial paced cycle length of 600 msec, increased during recainam loading infusion by 44%, from 38.8 ± 2.8 to 53.0 ± 5.4 msec; intranodal conduction time increased by 10%, from 102.0 ± 5.5 to 112.1 ± 5.2 msec; and infranodal conduction time increased by 31% from 53.1 ± 3.0 to 70.7 ± 3.8 msec. Slowed conduction persisted during washout. The mean right atrial effective refractory period was significantly prolonged (+7% at 600 msec cycle length and +8% at 450 msec cycle length, P < 0.05 and P < 0.01, respectively) during recainam loading and remained so during washout. However, the mean effective refractory period of the atrioventricular node was significantly prolonged only during the recainam loading infusion while pacing at 450-msec cycle length (+8%, P < 0.05). In contrast, the mean effective refractory period of the right ventricle was not changed during or immediately after the infusion, but was significantly shortened 30 minutes later (-4%, P < 0.05). Two of 25 patients (8%) developed adverse reactions requiring termination of the infusion. Five other patients (20%) developed less serious side effects during the recainam infusion, all of which resolved spontaneously and did not require termination of the infusion. The results demonstrate that recainam prolongs conduction in atrial, ventricular, and specialized cardiac conduction tissues. Recainam also prolongs atrial refractory periods, but has little or no effect on the sinus node or on AV nodal and right ventricular refractory periods. Thus, recainam is a Class I antiarrhythmic agent with a combination of electrophysiological properties suggesting its potential utility in the treatment of atrial and ventricular arrhythmias.

AB - This open-label, multicenter study was designed to assess the electrophysiological properties of intravenous recainam, an investigational Class I antiarrhythmic agent. In 25 patients undergoing electrophysiological studies for the evaluation of arrhythmias, recainam was administered intravenously in a loading infusion (0.1 mg/kg/min) for 40 minutes, followed by a maintenance infusion (0.02 mg/kg/min) until the completion of the study. Electrophysiological measurements were obtained at baseline, 30 minutes after initiation of the loading infusion, and 30 minutes after termination of the infusion during washout. Conduction intervals, refractory periods, and sinus node recovery times were measured during sinus rhythm and during atrial or ventricular pacing. Vital signs were obtained and recorded before, during, and after recainam infusion. The results showed no change in mean arterial pressure, but heart rate increased slightly by 4 beats/min following recainam infusion. Recainam produced a generalized slowing of intracardiac conduction. The mean intraatrial conduction time, measured at an atrial paced cycle length of 600 msec, increased during recainam loading infusion by 44%, from 38.8 ± 2.8 to 53.0 ± 5.4 msec; intranodal conduction time increased by 10%, from 102.0 ± 5.5 to 112.1 ± 5.2 msec; and infranodal conduction time increased by 31% from 53.1 ± 3.0 to 70.7 ± 3.8 msec. Slowed conduction persisted during washout. The mean right atrial effective refractory period was significantly prolonged (+7% at 600 msec cycle length and +8% at 450 msec cycle length, P < 0.05 and P < 0.01, respectively) during recainam loading and remained so during washout. However, the mean effective refractory period of the atrioventricular node was significantly prolonged only during the recainam loading infusion while pacing at 450-msec cycle length (+8%, P < 0.05). In contrast, the mean effective refractory period of the right ventricle was not changed during or immediately after the infusion, but was significantly shortened 30 minutes later (-4%, P < 0.05). Two of 25 patients (8%) developed adverse reactions requiring termination of the infusion. Five other patients (20%) developed less serious side effects during the recainam infusion, all of which resolved spontaneously and did not require termination of the infusion. The results demonstrate that recainam prolongs conduction in atrial, ventricular, and specialized cardiac conduction tissues. Recainam also prolongs atrial refractory periods, but has little or no effect on the sinus node or on AV nodal and right ventricular refractory periods. Thus, recainam is a Class I antiarrhythmic agent with a combination of electrophysiological properties suggesting its potential utility in the treatment of atrial and ventricular arrhythmias.

UR - http://www.scopus.com/inward/record.url?scp=0025777224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025777224&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 1129

EP - 1137

JO - PACE - Pacing and Clinical Electrophysiology

JF - PACE - Pacing and Clinical Electrophysiology

SN - 0147-8389

IS - 7

ER -